ClinicalTrials.gg
RecruitingNCT07146451TOCOKIDSUpdated Feb 13, 2026

6-year Outcomes in Children After Nifedipine vs Placebo for Preterm Prelabor Rupture of Membranes at 22-33 Weeks

An observational study in Children Born to Mothers Enrolled in the TOCOPROM Trial, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 6 Years to 78 Months. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
480
Ages
6 Years to 78 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 7 under way, 2 of them phase 3. Premature Birth · Assistance Publique - Hôpitaux de Paris.

Started
2025
the only one that year
Observational
6 of 26
2 open now
Registered
25th of 26
by date

Among the 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2025, is one of 6 observational ones, and was the 25th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

6 of the 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 6 Years to 78 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the neurodevelopment at age 6 of children born to women with preterm prelabor rupture of membranes at 22 to 33 weeks of gestation, after antenatal exposure to nifedipine vs placebo.

Read the detailed description

Preterm prelabor rupture of membranes (PPROM) complicates 3% of pregnancies and accounts for one-third of preterm births. It is a leading cause of neonatal mortality and morbidity and increases the risk of maternal infectious morbidity. In cases of early PPROM (22 to 33 completed weeks' gestation), expectant management is recommended in the absence of labor, chorioamnionitis or fetal distress. Antenatal steroids and antibiotics administration are recommended by international guidelines. However, there is no recommendation regarding tocolysis administration in the setting of PPROM. In theory, reducing uterine contractility should delay delivery and reduce the risks of prematurity and neonatal adverse consequences. Likewise, a prolongation of gestation may allow administering a corticosteroids complete course that is associated with a two-fold reduction of morbidity and mortality. However, tocolysis may prolong fetal exposure to inflammation and be associated with higher risk of materno-fetal infection, potentially associated with neonatal death or long-term sequelae, including cerebral palsy.

The investigators implemented the TOCOPROM randomized clinical trial to assess whether short-term (48 hr) tocolysis reduces perinatal morti-morbidity in cases of PPROM at 22-33 weeks. However, both short- and long-term outcomes should be taken into account to define the optimal treatment strategy. There are currently no data allowing to evaluate the impact of a short course of nifedipine versus placebo on neurodevelopmental outcomes in school-aged children born after PPROM. Therefore, following-up children born to mothers enrolled in the TOCOPROM trial, through a new study, the TOCOKIDS cohort, is a unique and timely opportunity to advance scientific knowledge and adapt clinical practices in France and worldwide.

The assessment at 6 years of age will consist in:

  • A self-administered parental questionnaire, completed online or on paper
  • Data collected from the health book, in particular the 6-year consultation
  • A short psychological assessment (45 minutes), performed remotely by a psychologist through video conference.
03

Conditions studied

  • Children Born to Mothers Enrolled in the TOCOPROM Trial

Browse trials for

Keywords

  • Prematurity
  • Nifedipine
  • Psychological assessment
  • Neurodevelopment
  • School age
  • Preterm prelabor rupture of membranes
04

Who can participate

Ages eligible
6 Years to 78 Months
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children born to women enrolled in the TOCOPROM trial reaching the age of 6 years

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All children born to mothers enrolled in the TOCOPROM trial who consented to participate in the 2-year follow-up and who agreed to be contacted for the 6-year follow-up
  • Alive at 6 years
  • Internet access, including access to a good-quality video-conference system (only for the psychological evaluation)
  • Non opposition of the holders of the exercise of parental authority

Exclusion criteria

Exclusion Criteria:

  • Major malformations and/or chromosomal aberrations evidenced after birth
  • Impossibility to contact the family
  • Opposition to participate in the follow-up
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
480 participants (estimated)
Patient registry
No

Groups and cohorts

  • Nifedipine

    Exposure during pregnancy to Oral Nifedipine 20 mg LP (between 22 to 33 weeks of gestation): Loading dose at T0 and T0.5 (i.e. 30 min), total=2x20 mg Maintenance dose: Oral Nifedipine 20 mg LP at T3, then 1 pill every 8 hours for 48 hours (i.e. T11, T19, T27, T35 and T43, total=6x20 mg)

    Other: Self-administered parental questionnaire

  • Placebo

    Exposure during pregnancy to oral placebo of nifedipine (between 22 to 33 weeks of gestation) at T0, T0.5, T3, T11, T19, T27, T35 and T43

    Other: A short psychological assessment performed online

Interventions

  • OtherSelf-administered parental questionnaire

    A self-administered parental questionnaire, completed online or on paper, to assess different dimension of neurodevelopment

  • OtherA short psychological assessment performed online

    NEMI-3: an intelligence test administered by a psychologist measuring a fluid and crystallised intelligence. The test consists of 117 spoken and visual questions, for a total administration time of 45 min. Results are expressed in the form of standard indices (mean 100, standard deviation 15) that facilitate comparisons with the results obtained on other intelligence scales. Results will be classified as normal, mild delay (between 1 and \<2 standard deviation \[SD\] below the mean) or severe delay (≥2 SD).

06

What researchers measure

Primary outcomes

  1. Cerebral palsy at 6 years of age.

    Cerebral palsy assessed using the Gross Motor Function Classification System (GMFCS), a five-level classification based on the child's current gross motor abilities, limitations in gross motor function, and need for assistive technology and wheeled mobility. Severe/moderate cerebral palsy (GMFCS≥2). Mild cerebral palsy (GMFCS-1).

    Time frame: Up to 6 months after inclusion.

  2. Developmental Coordination Disorder at 6 years of age.

    Measured using the Developmental Coordination Disorder Questionnaire - European French (DCDQ-FE), a brief parent questionnaire (15 items) designed to screen for gross and fine motor skills and coordination disorders in children, aged 5 to 15 years. Total score=15-56: indication of a risk of DCD or suspected of a risk of DCD. Total score=57-75: probably no DCD.

    Time frame: Up to 6 months after inclusion.

  3. Language at 6 years of age

    Language assessed using the verbal communication subscale (4 items) of the 5-15R scale, covering comprehension, expressive language skills and verbal communication, with an extra question on the impact of language and communication difficulties on daily activities. Mean (SD). Reference to cut-off scores in relation to the 90 and 98 percentiles (%).

    Time frame: Up to 6 months after inclusion.

  4. Behavior at 6 years of age.

    Behavior assessed using the Strengths and Difficulties Questionnaire (SDQ), a brief behavioral screening questionnaire (25 items), designed to screen for symptoms of hyperactivity inattention, emotional, conduct, and peer problems among 2-17 year olds. Mean (SD). Abnormal: \>90th percentile. Mildly abnormal: 80-90 percentile.

    Time frame: Up to 6 months after inclusion.

  5. Executive functions at 6 years of age.

    Executive functions measured using the Childhood Executive Functioning Inventory (CHEXI), a rating instrument (24 items) for parents that was developed for measuring executive functioning in children age 4-12. It includes four different subscales tapping working memory, planning, regulation and inhibition, combined into two global scales: working memory (working memory and planning subscales) and inhibition (inhibition and regulation subscales). Normative data are not yet available. Abnormality will be defined considering a cut-off or deviation compared to the mean score, depending on the literature.

    Time frame: Up to 6 months after inclusion.

Secondary outcomes

  1. Vital status at 6 years of age.

    Whether the child is alive or not at years of age.

    Time frame: Up to 6 months after inclusion.

  2. Neurodevelopmental impairment.

    Moderate-to-severe impairment (severe/moderate cerebral palsy, and/or abnormal SDQ score, and/or NEMI-3 ≥2 SD below the mean, and/or blindness, and/or deafness), mild impairment (mildly abnormal scores or mild impairment) vs no neurodevelopmental impairment.

    Time frame: Up to 6 months after inclusion.

  3. Survival without any neurodevelopmental impairment at 6 years of age.

    Survival without any neurodevelopmental impairment (as defined in the primary endpoint, and then including also cognitive impairment).

    Time frame: Up to 6 months after inclusion.

  4. Survival without moderate-to-severe neurodevelopmental impairment at 6 years of age.

    Survival without moderate-to-severe neurodevelopmental impairment (i.e. severe/moderate cerebral palsy, and/or abnormal SDQ score, and/or NEMI-3 ≥2 SD below the mean, and/or blindness, and/or deafness).

    Time frame: Up to 6 months after inclusion.

  5. Growth at 6 years of age.

    Height compulsory examination in the sixth year, reported in the health book.

    Time frame: Up to 6 months after inclusion.

  6. Growth at 6 years of age

    Weight. Compulsory examination in the sixth year, reported in the health book

    Time frame: Up to 6 months after inclusion

  7. Health at 6 years of age.

    Arterial pressure. Compulsory examination in the sixth year, reported in the health book.

    Time frame: Up to 6 months after inclusion.

  8. Health at 6 years of age

    chronic diseases, compulsory examination in the sixth year, reported in the health book

    Time frame: Up to 6 months after inclusion

  9. Health at 6 years of age

    oral health. Compulsory examination in the sixth year, reported in the health book

    Time frame: Up to 6 months after inclusion

  10. Vision at 6 years of age.

    Visual acuity, any vision problem mentioned. Compulsory examination in the sixth year, reported in the health book.

    Time frame: Up to 6 months after inclusion.

  11. Hearing at 6 years of age.

    Hearing test. Compulsory examination in the sixth year, reported in the health book.

    Time frame: Up to 6 months after inclusion.

  12. Development at 6 years of age.

    Data reported in the health book during the compulsory examination in the sixth year.

    Time frame: Up to 6 months after inclusion.

  13. Language at 6 years of age.

    Language test. Compulsory examination in the sixth year, reported in the health book.

    Time frame: Up to 6 months after inclusion.

  14. Behaviour at 6 years of age.

    Data reported in the health book during the compulsory examination in the sixth year.

    Time frame: Up to 6 months after inclusion.

  15. Cognition at 6 years of age.

    NEMI-3: an intelligence test administered by a psychologist measuring a fluid and crystallised intelligence. The test consists of 117 spoken and visual questions, for a total administration time of 45 min. Results are expressed in the form of standard indices (mean 100, standard deviation 15) that facilitate comparisons with the results obtained on other intelligence scales. Results will be classified as normal, mild delay (between 1 and \<2 standard deviation \[SD\] below the mean) or severe delay (≥2 SD).

    Time frame: Up to 6 months after inclusion.

  16. Feasibility of performing an online psychological evaluation.

    Acceptability E-Scale (adapted - 3 items), participation and completion rates, technical difficulties.

    Time frame: Up to 6 months after inclusion.

  17. Parent-reported health and development.

    Self-reported. Perceived health and development of the child, parental concerns about health and development, and professional diagnoses of health conditions (e.g., asthma, respiratory problems, etc.).

    Time frame: Up to 6 months after inclusion.

  18. Parent-reported Health-Related Quality of Life.

    PedsQL Short Form - 15 items. All items will be added up and linearly transformed on a scale between 0 and 100, a higher score indicating a better HRQoL. Physical and psychosocial functioning will be further assessed using the corresponding subscales. Poor HRQoL, physical or psychosocial functioning will be defined using thresholds compatible with a severe health condition.

    Time frame: Up to 6 months after inclusion.

  19. Parent-reported school difficulties

    Ad-hoc questions

    Time frame: Up to 6 months after inclusion

  20. Maternal self-perceived health

    Minimum European Health Module - 1 item

    Time frame: Up to 6 months after inclusion

  21. Maternal mental health

    PHQ-4 (anxiety and depression) - 4 items

    Time frame: Up to 6 months after inclusion

  22. Maternal well-being

    WHO-5 Well-Being Index - 5 items

    Time frame: Up to 6 months after inclusion

  23. Maternal quality of life

    WHOQOL bref FR - 1 item

    Time frame: Up to 6 months after inclusion

07

Study locations

1 of 1 sites recruiting
  • Trousseau University Hospital
    Paris, France 75012, France
    Recruiting
08

References and documents

Publications

  • Houtzager BA, Hogendoorn SM, Papatsonis DN, Samsom JF, van Geijn HP, Bleker OP, van Wassenaer AG. Long-term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG. 2006 Mar;113(3):324-31. doi: 10.1111/j.1471-0528.2006.00851.x. PubMed 16487205 ↗
  • Van De Water M, Kessel ET, De Kleine MJ, Oei SG. Tocolytic effectiveness of nifedipine versus ritodrine and follow-up of newborns: a randomised controlled trial. Acta Obstet Gynecol Scand. 2008;87(3):340-5. doi: 10.1080/00016340801913189. PubMed 18307075 ↗
  • van Vliet E, Seinen L, Roos C, Schuit E, Scheepers H, Bloemenkamp K, Duvekot JJ, van Eyck J, Kok JH, Lotgering FK, van Baar A, van Wassenaer-Leemhuis AG, Franssen MT, Porath MM, van der Post J, Franx A, Mol B, Oudijk MA. Maintenance tocolysis with nifedipine in threatened preterm labour: 2-year follow up of the offspring in the APOSTEL II trial. BJOG. 2016 Jun;123(7):1107-14. doi: 10.1111/1471-0528.13586. Epub 2015 Aug 27. PubMed 26330379 ↗
  • van Winden T, Klumper J, Kleinrouweler CE, Tichelaar MA, Naaktgeboren CA, Nijman TA, van Baar AL, van Wassenaer-Leemhuis AG, Roseboom TJ, Van't Hooft J, Roos C, Mol BW, Pajkrt E, Oudijk MA. Effects of tocolysis with nifedipine or atosiban on child outcome: follow-up of the APOSTEL III trial. BJOG. 2020 Aug;127(9):1129-1137. doi: 10.1111/1471-0528.16186. Epub 2020 Mar 29. PubMed 32124520 ↗
  • Wilson A, Hodgetts-Morton VA, Marson EJ, Markland AD, Larkai E, Papadopoulou A, Coomarasamy A, Tobias A, Chou D, Oladapo OT, Price MJ, Morris K, Gallos ID. Tocolytics for delaying preterm birth: a network meta-analysis (0924). Cochrane Database Syst Rev. 2022 Aug 10;8(8):CD014978. doi: 10.1002/14651858.CD014978.pub2. PubMed 35947046 ↗
  • Lorthe E, Kayem G; TOCOPROM Study Group and the GROG (Groupe de Recherche en Obstetrique et Gynecologie). Tocolysis in the management of preterm prelabor rupture of membranes at 22-33 weeks of gestation: study protocol for a multicenter, double-blind, randomized controlled trial comparing nifedipine with placebo (TOCOPROM). BMC Pregnancy Childbirth. 2021 Sep 8;21(1):614. doi: 10.1186/s12884-021-04047-2. PubMed 34496799 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2033, 95 months after the start.

Of 373 non-industry observational studies under Premature Birth, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 63. This study's planned 95 months is above that.

Counting every sponsor, half of 388 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2025
First posted
Aug 28, 2025
StartActual
Oct 28, 2025
Primary completionEst.
Sep 2033
CompletionEst.
Sep 2034
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07146451
Collaborators
URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Oct 28, 2025
Primary completion
Sep 2033 (estimated)
Completion
Sep 2034 (estimated)
Last update
Feb 13, 2026

Study contacts

Gilles KAYEM, MD,PhD
Contact
gilles.kayem@aphp.fr
01 44 73 51 18 ext. +33
Nelly Briand, PhD
Contact
nelly.briand@aphp.fr
01 44 38 18 62 ext. +33
Gilles KAYEM, MD,PhD
principal investigator · Université Paris Cité and Université Sorbonne Paris Nord, Paris, France. DHU Risks in Pregnancy, Paris Descartes University, Trousseau University Hospital
Elsa LORTHE, RM,PhD
study director · Université Paris Cité and Université Sorbonne Paris Nord, Paris, France.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion